23andMe, Genentech to analyze 3,000 Parkinson’s genomes

(Reuters) – Privately held 23andMe Inc and Genentech said on Tuesday they will work together to generate whole genome sequencing data for about 3,000 people with Parkinson’s disease, in order to identify new therapeutic targets for treating the degenerative neurological condition.

—> Read More Here


Leave a Reply

Your email address will not be published. Required fields are marked *